Affimed Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Affimed han disminuido a una tasa media anual de -37.5%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 2.6% al año.

Información clave

-37.5%

Tasa de crecimiento de los beneficios

-19.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	2.6%
Rentabilidad financiera	-183.3%
Margen neto	-761.4%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20

Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Feb 15

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb 03

Affimed N.V. initiates equity offering

Jan 12

Affimed inks €25M debt financing deal with Silicon Valley Bank

Jan 11

Affimed updates on product pipeline and cash balances

Jan 07

Affimed (NASDAQ:AFMD) Has Debt But No Earnings; Should You Worry?

Dec 25

What Did Affimed's (NASDAQ:AFMD) CEO Take Home Last Year?

Dec 04

Desglose de ingresos y gastos

Cómo gana y gasta dinero Affimed. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:AFMD Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	14	-106	25	93
30 Sep 23	21	-119	26	110
30 Jun 23	34	-111	29	114
31 Mar 23	39	-101	32	110
31 Dec 22	43	-86	32	97
30 Sep 22	42	-76	31	93
30 Jun 22	36	-76	30	87
31 Mar 22	38	-76	27	88
31 Dec 21	42	-58	24	81
30 Sep 21	41	-49	21	71
30 Jun 21	43	-38	18	60
31 Mar 21	36	-32	15	50
31 Dec 20	29	-41	14	50
30 Sep 20	22	-39	12	46
30 Jun 20	14	-44	12	47
31 Mar 20	15	-43	11	47
31 Dec 19	21	-32	10	44
30 Sep 19	41	-11	11	43
30 Jun 19	39	-12	10	41
31 Mar 19	35	-9	10	37
31 Dec 18	24	-19	10	35
30 Sep 18	2	-35	9	28
30 Jun 18	2	-31	8	24
31 Mar 18	2	-31	8	22
31 Dec 17	2	-30	8	21
30 Sep 17	3	-29	8	22
30 Jun 17	3	-31	9	25
31 Mar 17	5	-32	9	28
31 Dec 16	6	-32	9	30
30 Sep 16	7	-33	8	31
30 Jun 16	7	-30	8	29
31 Mar 16	7	-27	8	26
31 Dec 15	8	-20	8	22
30 Sep 15	7	-19	8	19
30 Jun 15	7	-5	6	15
31 Mar 15	6	14	0	7
31 Dec 14	4	0	3	9
30 Sep 14	8	2	2	11
30 Jun 14	7	-16	5	11
31 Mar 14	6	-38	11	18
31 Dec 13	6	-26	7	14

Ingresos de calidad: AFMD actualmente no es rentable.

Margen de beneficios creciente: AFMD actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AFMD no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 37.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de AFMD en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: AFMD no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: AFMD tiene una rentabilidad financiera negativa (-183.26%), ya que actualmente no es rentable.

Affimed Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Recent updates

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

New minor risk - Market cap size

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Consensus revenue estimates decrease by 22%

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Now 26% undervalued after recent price drop

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed Q2 2022 Earnings Preview

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed: Preparing For Key Inflection Points

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Affimed Stock: 3 Points For The Bulls

Consensus revenue estimates fall by 23%

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13

Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab

Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center

Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020)

Affimed: Preparing For A Bullish 2022

Second quarter 2021 earnings released: €0.16 loss per share (vs €0.15 loss in 2Q 2020)

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Consensus EPS estimates increase to -€0.25

Affimed: Current Fall And Future Prospects

First quarter 2021 earnings released: EPS €0.012 (vs €0.11 loss in 1Q 2020)